A longer study (mean follow-up of 3 years), found a lower risk for a composite outcome of kidney replacement therapy, or kidney failure-related hospitalization or death in initiators of GLP-1 RAs compared with DPP4i [29]

Key Points Animal studies suggest that endogenous, central glucagon-like peptide 1 (GLP-1) regulates both short-term and long-term energy balance, potentially via activation of hindbrain and hypothalamic GLP-1 receptors (GLP1R), respectively Endogenous peripheral GLP-1 may limit meal size by activation of GLP1R on local vagal afferent nerves and stimulation of a gutbrain feedback loop Increasing GLP1R activity by administering GLP-1 receptor agonists reduces food intake and promotes weight loss in humans, but the extent to which endogenous GLP-1 regulates energy balance in humans remains unknown Although diabetes mellitus and obesity appear to be associated with altered GLP-1 system activity, GLP1R agonists retain their efficacy in these contexts, making them a viable therapeutic tool A better understanding of how endogenous central and peripheral GLP-1 regulate energy balance has the potential to maximize our application of GLP-1-based therapies for the treatment of obesity This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 189,00 per year only 15,75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

In the pancreas, they stimulate glucose-dependent insulin secretion, meaning insulin is released only when blood glucose levels are elevated, which reduces the risk of hypoglycemia compared to some other diabetes medications
Acid ceramidase modulates the lipid profile and exacerbates sensitivity to ferroptosis in WI-38 replicative senescent cells by David Soriano-Castell, Marie Goujon, Nawab John Dar, Antonio Currais & Pamela Maher
203 The maintenance of telomeres is influenced by continuous exposure of cells to free radicals